Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

Cited In for PubMed (Select 17617523)

1.

Risk-reducing surgery in hereditary gynecological cancer: Clinical applications in Lynch syndrome and hereditary breast and ovarian cancer.

Adachi M, Banno K, Yanokura M, Iida M, Nakamura K, Nogami Y, Umene K, Masuda K, Kisu I, Ueki A, Hirasawa A, Tominaga E, Aoki D.

Mol Clin Oncol. 2015 Mar;3(2):267-273. Epub 2014 Nov 20.

2.

Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.

Ohman AW, Hasan N, Dinulescu DM.

Front Oncol. 2014 Nov 18;4:322. doi: 10.3389/fonc.2014.00322. eCollection 2014. Review.

3.

BRCA-associated ovarian cancer: from molecular genetics to risk management.

Girolimetti G, Perrone AM, Santini D, Barbieri E, Guerra F, Ferrari S, Zamagni C, De Iaco P, Gasparre G, Turchetti D.

Biomed Res Int. 2014;2014:787143. doi: 10.1155/2014/787143. Epub 2014 Jul 22. Review.

4.

An unusual BRCA mutation distribution in a high risk cancer genetics clinic.

Nelson-Moseke AC, Jeter JM, Cui H, Roe DJ, Chambers SK, Laukaitis CM.

Fam Cancer. 2013 Mar;12(1):83-7. doi: 10.1007/s10689-012-9581-z.

5.

Ovarian metastases resection from extragenital primary sites: outcome and prognostic factor analysis of 147 patients.

Li W, Wang H, Wang J, L V F, Zhu X, Wang Z.

BMC Cancer. 2012 Jul 3;12:278. doi: 10.1186/1471-2407-12-278.

6.

Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility.

Landon G, Stewart J, Deavers M, Lu K, Sneige N.

Gynecol Oncol. 2012 Jun;125(3):683-6. doi: 10.1016/j.ygyno.2012.03.009. Epub 2012 Mar 13.

7.

A screening and prevention programme serving an ethnically diverse population of women at high risk of developing breast and/or ovarian cancer.

Smith J, Baer L, Blank S, Dilawari A, Carapetyan K, Alvear M, Utate M, Curtin J, Muggia F.

Ecancermedicalscience. 2009;3:123. doi: 10.3332/ecancer.2008.123. Epub 2009 Mar 16.

8.

Exercise lowers estrogen and progesterone levels in premenopausal women at high risk of breast cancer.

Kossman DA, Williams NI, Domchek SM, Kurzer MS, Stopfer JE, Schmitz KH.

J Appl Physiol (1985). 2011 Dec;111(6):1687-93. doi: 10.1152/japplphysiol.00319.2011. Epub 2011 Sep 8.

9.

Factors associated with altered long-term well-being after prophylactic salpingo-oophorectomy among women at increased hereditary risk for breast and ovarian cancer.

Touboul C, Uzan C, Ichanté JL, Caron O, Dunant A, Dauchy S, Gouy S, de Paillerets BB, Morice P, Delaloge S.

Oncologist. 2011;16(9):1250-7. doi: 10.1634/theoncologist.2010-0336. Epub 2011 Jul 17.

10.

Assessing ovarian cancer risk when considering elective oophorectomy at the time of hysterectomy.

Vitonis AF, Titus-Ernstoff L, Cramer DW.

Obstet Gynecol. 2011 May;117(5):1042-50. doi: 10.1097/AOG.0b013e318212fcb7.

11.

Pathology of hereditary breast cancer.

van der Groep P, van der Wall E, van Diest PJ.

Cell Oncol (Dordr). 2011 Apr;34(2):71-88. doi: 10.1007/s13402-011-0010-3. Epub 2011 Feb 19. Review.

12.

Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer.

Pruthi S, Gostout BS, Lindor NM.

Mayo Clin Proc. 2010 Dec;85(12):1111-20. doi: 10.4065/mcp.2010.0414. Review.

13.

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR.

JAMA. 2010 Sep 1;304(9):967-75. doi: 10.1001/jama.2010.1237.

14.

Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.

Grann VR, Patel PR, Jacobson JS, Warner E, Heitjan DF, Ashby-Thompson M, Hershman DL, Neugut AI.

Breast Cancer Res Treat. 2011 Feb;125(3):837-47. doi: 10.1007/s10549-010-1043-4. Epub 2010 Jul 20.

15.

BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?

Tagliaferri P, Ventura M, Baudi F, Cucinotto I, Arbitrio M, Di Martino MT, Tassone P.

J Ovarian Res. 2009 Oct 13;2:14. doi: 10.1186/1757-2215-2-14.

16.

The molecular genetics of breast cancer and targeted therapy.

Suter R, Marcum JA.

Biologics. 2007 Sep;1(3):241-58.

17.

Three-dimensional ovarian organ culture as a tool to study normal ovarian surface epithelial wound repair.

Jackson KS, Inoue K, Davis DA, Hilliard TS, Burdette JE.

Endocrinology. 2009 Aug;150(8):3921-6. doi: 10.1210/en.2008-1674. Epub 2009 May 7.

18.

Breast cancer in young women and its impact on reproductive function.

Hickey M, Peate M, Saunders CM, Friedlander M.

Hum Reprod Update. 2009 May-Jun;15(3):323-39. doi: 10.1093/humupd/dmn064. Epub 2009 Jan 27. Review.

19.

Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.

Rebbeck TR, Kauff ND, Domchek SM.

J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442. Epub 2009 Jan 13.

20.

Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary.

Messina MJ, Wood CE.

Nutr J. 2008 Jun 3;7:17. doi: 10.1186/1475-2891-7-17. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk